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Discovery of Inhibitors that Elucidate
the Role of UCH-L1 Activity
in the H1299 Lung Cancer Cell Line
identity to UCH-L1), is expressed in all tissues, including
brain [1, 8]. Despite the high sequence homology, the
in vitro hydrolytic activities of the two enzymes are very
different; UCH-L3 is more than 200-fold more active (kcat)
toward a model ubiquitin amide substrate [9].
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Brigham and Women’s Hospital In addition to its hydrolase activity, UCH-L1 can cata-
lyze ubiquityl transfer to a lysine residue (presumably2 Department of Neurology
Harvard Medical School Lys63) on another ubiquitin molecule (Figure 1A). This
ligase activity requires dimerization of the enzyme [9].3 Harvard Center for Neurodegeneration and Repair
4 Laboratory for Drug Discovery in Neurodegeneration UCH-L3 has little or no ligase activity as compared to
UCH-L1. This ligase activity may explain why a common65 Landsdowne Street
Cambridge, Massachusetts 02139 polymorphism of UCH-L1 (S18Y) is linked to a reduction
in the risk of Parkinson’s disease [10–15]. In addition
to its role in PD, UCH-L1 may also play a role in the
progression of certain cancers. The UCH-L1 protein isSummary
expressed in many primary lung tumors and lung tumor
cell lines but is not detectable in normal lung tissueNeuronal ubiquitin C-terminal hydrolase (UCH-L1) has
[16–21]. A positive correlation exists between UCH-L1been linked to Parkinson’s disease (PD), the progres-
expression and tumor progression, suggesting thatsion of certain nonneuronal tumors, and neuropathic
UCH-L1 may play a role in lung cancer tumorigenesispain. Certain lung tumor-derived cell lines express
[16]. Expression of UCH-L1 also correlates with tumorUCH-L1 but it is not expressed in normal lung tissue,
progression in colorectal cancer [22]. Collectively, thesesuggesting that this enzyme plays a role in tumor pro-
data suggest that UCH-L1 is either (1) driving tumorgression, either as a trigger or as a response. Small-
proliferation and/or cell invasion, in which case UCH-molecule inhibitors of UCH-L1 would be helpful in
L1 would be a potential therapeutic target for certaindistinguishing between these scenarios. By utilizing
types of cancer, or (2) expressed in response to tumorhigh-throughput screening (HTS) to find inhibitors and
growth.traditional medicinal chemistry to optimize their affin-
We chose to probe the relationship of UCH-L1 andity and specificity, we have identified a class of isatin
tumor progression by a forward chemical genetics ap-O-acyl oximes that selectively inhibit UCH-L1 as com-
proach [23, 24] starting with a screen for inhibitors ofpared to its systemic isoform, UCH-L3. Three repre-
UCH-L1 enzymatic activity. The only known inhibitor ofsentatives of this class (30, 50, 51) have IC50 values of
UCH-L1, the C-terminal aldehyde of ubiquitin, is not useful0.80–0.94 M for UCH-L1 and 17–25 M for UCH-L3.
for studies in cell or animal models [25, 26]. We describeThe Ki of 30 toward UCH-L1 is 0.40 M and inhibition
here a high-throughput UCH-L1 enzymatic assay, theis reversible, competitive, and active site directed. Two
application of that assay to screen a library of 42,000isatin oxime inhibitors increased proliferation of the
drug-like compounds, and the optimization of the “hits”H1299 lung tumor cell line but had no effect on a lung
from that screen. One class of inhibitors, O-acyl oximetumor line that does not express UCH-L1. Inhibition
derivatives of isatins, demonstrated that UCH-L1 activityof UCH-L1 expression in the H1299 cell line using RNAi
opposes proliferation. This class of compounds mayhad a similar proproliferative effect, suggesting that
also be useful for elucidating the etiological role of UCH-the UCH-L1 enzymatic activity is antiproliferative and
L1 in PD [9].that UCH-L1 expression may be a response to tumor
growth. The molecular mechanism of this response
remains to be determined.
Results
Introduction Design of UCH-L1 HTS Screen
Both UCH-L3 and UCH-L1 catalyze the hydrolysis of
Ubiquitin C-terminal hydrolase (UCH-L1) is one of the ubiquitin-AMC (Ub-AMC, 7-amido-4-methylcoumarin C
most abundant proteins in the brain, constituting up to terminus derivative of ubiquitin) [6, 9]. Upon formation
2% of total protein [1, 2]. It is normally expressed only of the acyl enzyme intermediate, AMC is released from
in neurons and testis [1, 2]. UCH-L1 is a 223 amino acid the ubiquitin C terminus (Figure 1A). The free AMC exhib-
cysteine hydrolase that contains the typical active site its enhanced fluorescence, and the rate of AMC release
triad of cysteine, histidine, and aspartic acid [3] and was monitored by fluorescence spectroscopy (em 
catalyzes hydrolysis of C-terminal esters and amides of 460 nm, ex 380 nm), which was plotted against reac-
ubiquitin [4]. It is believed to play a key role in processing tion time (Figure 1B). In each reaction, 300 pM of UCH-
polyubiquitin and/or ubiquitylated proteolytic peptides L1 was reacting with 100 nM of Ub-AMC substrate. The
[3–7]. An isoform of the enzyme, UCH-L3 (52% sequence concentration of UCH-L1 was significantly lower than
the dimerization constant (at M range); thus, only mo-
nomeric UCH-L1 should be present [9]. In addition, since*Correspondence: plansbury@rics.bwh.harvard.edu
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Figure 1. The High-Throughput Screen Targeted Acyl Enzyme Formation
(A) A schematic mechanism of UCH-L1 ligase and hydrolase activities, both of which proceed via acyl(ubiquityl) enzyme formation. Acyl
enzyme formation was targeted by the screen described herein (see target). The rectangle is meant to signify the equilibrium mixture of
monomeric and dimeric forms of UCH-L1. The dimer may be responsible for ligase activity [9].
(B) The fluorogenic substrate used (Ub-AMC) produced a fluorescent amine product, AMC (blue sunburst). The release of nonubiquitinated
AMC upon acyl enzyme formation was monitored by fluorescence spectroscopy.
the reaction was run with excess substrate, multiple (1) molecular weights less than 600 D, (2) log P less than
5, (3) fewer than 5 H bond donors, and (4) fewer thanturnovers are observed, so the assay cannot distinguish
between inhibitors of ubiquityl enzyme formation and 10 H bond acceptors. From the primary robot-assisted
screen, 1% of the compounds showed inhibitory activityinhibitors of ubiquityl enzyme breakdown (subsequent
data presented below strongly suggest that our hits are (60%) toward UCH-L1. About two-thirds of these com-
pounds were eliminated after repeated manual analysisactive site directed and thus probably inhibit the former
step). The identification of specific inhibitors for UCH-L1 (secondary screen, see Experimental Procedures). Fi-
nally, only those compounds that showed dose-depen-acyl enzyme formation was accomplished by screening
compound libraries for their ability to inhibit enzyme- dent inhibition of UCH-L1 and did not interfere with AMC
fluorescence were subjected to IC50 determinationmediated cleavage of the AMC fluorophore from ubiqui-
tin-AMC. A minimum reaction time of 30 min was re- against UCH-L1 and/or UCH-L3 (see Experimental Pro-
cedures).quired to screen 3000 compounds. The concentration
of UCH-L1 and its substrate Ub-AMC were optimized
for the HTS to yield a linear velocity of AMC release over Compounds from the Libraries Showed Various
Degrees of Inhibitory Activity toward UCH-L1a period of at least half an hour (Figure 1B), and thus
the decrease in AMC fluorescence emission observed Among the compounds that emerged from the screening
process, a set of oxime derivatives of isatin (1–8) demon-after quenching of the reaction correlates to enzyme
inhibition. The Z factor, a standard statistical parameter strated micromolar IC50 values toward UCH-L1 and a
consistent preference for UCH-L1 over UCH-L3 (Figurefor HTS assays that is reflective of both the assay signal
dynamic range and the data variation associated with 2A). Molecules of this class, albeit not these specific
acyl oximes, have previously been reported to havethe signal measurements, was determined to be 0.61
(n  51 for both positive and negative controls in three antitelomerase activity [29], ion channel-activating ac-
tivity [30], antagonism of excitatory amino acids [31],separate 384-well plates), indicative of a robust HTS
assay (0.5) [27]. and inhibitory activity for c-Jun N-terminal kinase (JNK)
[32]. During the screening process, some inhibitors wereThe screening library consisted of 42,000 compounds
that, in general, had the following characteristics [28]: found to be selective for UCH-L3 over UCH-L1 (Figure
HTS for the Discovery of UCH-L1 Inhibitors
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Figure 2. Inhibitory Activities of the Compounds from the Initial Library
(A) A series of isatins from the initial library (1–8) showed inhibitory activity and selectivity for UCH-L1 over UCH-L3. A more detailed analysis
showed that these compounds have IC50 values for UCH-L1 ranging from 6 to 50 M with as much as a 5-fold selectivity for UCH-L1 (IC50
values indicated in black) over UCH-L3 (IC50 values indicated in red).
(B) Three compounds showed selectivity for UCH-L3 over UCH-L1. These compounds, menadione 9 (commonly known as vitamin K3), 10,
and 11, were selective for UCH-L3 (IC50 values indicated in red) over UCH-L1 (IC50 values indicated in black) by as much as 100-fold.
(C) A list of isatin derivatives that have IC50 values for UCH-L1 greater than 60 M. Note that only compounds with the indicated combinations
of R3 and R2 were in the library. Wavy lines bisect bonds to atoms indicated in central structure.
2B). These compounds included menadione 9 (vitamin the benzo portion of the isatin ring tolerated a variety
of substituents (R1).K3), 10, and 11, the latter of which is selective for UCH-
L3 over UCH-L1 by over 100-fold.
Continued Analysis of Isatin Oxime Structure-Activity
Relationship for UCH-L1 Inhibitory ActivityStructure-Activity Relationship Derived
from Analysis of Isatin Derivatives Oxime and O-acyl oxime derivatives of isatins were pre-
pared according to the following method (SupplementalEight isatin oximes (1–8) from the primary screen passed
the rigorous validation assays and were selective for Figure S1 at http://www.chembiol.com/cgi/content/full/
10/9/837/DC1). First, the isatins were deprotonated withUCH-L1. A more detailed analysis showed that this class
of compounds had IC50 values for UCH-L1 ranging from sodium hydride in DMF and then alkylated with various
benzyl or 2-phenethyl bromides to yield N-alkylated isat-6 M to 51 M with as much as 5-fold selectivity for
UCH-L1 over UCH-L3 (Figure 2A). The screening library ins. Next, these compounds were converted to their corre-
sponding oximes by treatment with hydroxylamine hy-also contained a subset of oxime isatins that had no
effect on UCH-L1 hydrolase activity (Figure 2C). Several drochloride in methanol:THF (1:1) and the presence of
NaOAc at room temperature. Finally, O-acylation wasgeneral trends can be drawn from these two sets of
compounds with respect to their ability to inhibit UCH- accomplished either with an acid chloride or an anhy-
dride in dichloromethane in the presence of pyridineL1. First, increasing the size of the substituent on R3
resulted in decreased activity (Figures 2A and 2C). Nei- (and in some cases 4-N, N-dimethylaminopyridine) to
give the O-acyl oxime isatin derivatives. The compoundsther long hydrocarbon chains nor bulky phenyl rings
yielded good inhibitors. Second, the phenyl substituent prepared for in vitro enzymatic activity evaluation are
shown in Tables 1 and 2.at the R2 position appeared to require a linker of at least
one carbon. All of the compounds that lacked such a The structure-activity relationship study was con-
ducted in order to increase UCH-L1 inhibitory potencylinker were inactive, although the absence of activity
may be partially due to the large R3 substituents. Finally, and selectivity for UCH-L1 over UCH-L3. First, the data
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values for UCH-L3 inhibition for 21 and 12 were 33 MTable 1. Comparison of the UCH-L1 Inhibitory Activity for
Acylated Oxime Isatin Derivatives versus Nonacylated and 40 M, respectively, suggesting that the acyl group
Oximes was not critical for UCH-L3 activity. In the most pro-
nounced case (14 versus 23), the acylated oxime re-
sulted in a 23-fold increase in activity toward UCH-L1
compared to the oxime.
Several conclusions can be drawn concerning inhibi-
tion of UCH-L1 by O-acyl oxime isatins (Table 2). A tether
length of one or two carbons between the heterocyclic
core and R2 is optimal. A tether length of zero (see pri-
mary library screening data, Figure 2C) and three atoms
(e.g., 36 and 41) resulted in diminished activity. Some
additional substitution of the tethering chain was permit-
ted (e.g., 13). However, other substituents were detri-
Acylated oxime isatin derivatives are shown in blue and nonacylated mental (e.g., 38, 42, and 46) to activity. Electron-with-
oximes are shown in red. drawing groups in the 3- and 4-positions of R2 (e.g., 1
and 18) were preferred over the 2-position (e.g., 19), but
disubstituted rings having one of the substituents at the
2-position were tolerated (e.g., 30 and 31). Likewise,shown in Table 1 suggested that acylation of the oxime
small electron-withdrawing groups (R1) in the 5- andgroup is critical for increasing potency toward UCH-L1,
6-positions of the heterocyclic core (e.g., 50, 51, 52, 55,but a similar increase in activity was not observed in
and 14) led to greater activity. Substitution at the hetero-the case of UCH-L3 (data not shown). For example,
cyclic ring’s 4-position was not tolerated (e.g., 20). Onlycompound 21 has an IC50 value of 12M and its acylated
small, unbranched alkyl groups (e.g., methyl) were per-derivative 12 has an IC50 value of 1.8 M for UCH-L1
mitted at the R3 position. Both long unbranched andinhibition, a 6.7-fold increase in activity. In contrast, IC50
small branched alkyl groups were not tolerated. These
O-acyl oxime isatins are soluble in aqueous solution
Table 2. IC50 Values of O-Acyl Oxime Isatin Derivatives with neutral pH, although small crystals of compounds
were observed at concentration of 5M in protein buffer
after 1 hr of incubation at room temperature. A summary
of the structure-activity relationship and the structures
of the three most potent inhibitors (30, 50, and 51) are
shown in Figure 3A.
As the potency toward UCH-L1 increased, the speci-
ficity was also improved (Table 2). The two best cases
tested were 30 and 51, which favored UCH-L1 over UCH-
L3 by 28- and 24-fold, respectively (Figure 3B). Both
compounds had submicromolar IC50 values for UCH-
L1 hydrolase activity. The widening gap between the
compounds’ activities toward UCH-L1 and UCH-L3 re-
sulted from an increase in UCH-L1 inhibitory activity,
with little or no change in UCH-L3 inhibitory activity.
Several other changes to the O-acyl oximes were
made to further explore the structure-activity relation-
ship (Figure 3C) for UCH-L1 inhibition. For example,
isatin derivatives 68 and 69 were not capable of inhib-
iting UCH-L1 enzymatic activity at the concentration
tested (100 M). Likewise, carbamate 64 and the acetyl
hydrazones 65 and 66 were prepared. In all cases the
UCH-L1 inhibitory activity was diminished (IC50  40
M). O-alkyl oxime 67 also had lower UCH-L1 inhibitory
activity, further supporting the importance of the O-acyl
oxime group for activity.
O-Acyl Oxime Compounds Are Reversible
Competitive Inhibitors of UCH-L1
Several experiments were performed to characterize the
inhibitory mechanism of the O-acyl oximes. Various
amounts of Ub-AMC were titrated against 1 nM UCH-
L1 in the presence of different concentrations of 30. The
resulting Michaelis-Menten plot showed an increase in
KM,app without affecting the kcat,app of the UCH-L1/Ub-AMC
HTS for the Discovery of UCH-L1 Inhibitors
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Figure 3. The Inhibitory Activity and Specificity of the Isatin Oxime Derivatives
(A) UCH-L1 inhibition structure-activity relationship summary for isatin oxime derivatives. Three potent inhibitors, 30, 50, and 51, are shown
at bottom.
(B) Compounds 30 and 51 show a strong preference for UCH-L1 over UCH-L3. IC50 curves of UCH-L1 (black) and UCH-L3 (red) for 30 and 51.
(C) Compounds related to 30 and 51 that showed a significant decrease in inhibitory activity toward UCH-L1 (IC50  40 M).
reaction (Figures 4A and 4B). This result suggested that these inhibitors occupy the enzyme active site. Finally,
thin-layer chromatography (TLC) and 1H NMR analyses30 is a competitive and reversible inhibitor of UCH-L1.
The linear fit of KM,app on [30] plot yielded a Ki value of of the reaction mixtures containing 30 or 14 (with or
without UCH-L1) after 2 hr of incubation showed no0.40 M (Figure 4C). This Ki is consistent with the value
(0.48 M) predicted from its IC50 (0.88 M) determined change in the compounds’ composition (data not
shown), demonstrating that they are stable in aqueousin separate experiments (Table 2), using the following
relationship for competitive inhibition (equation 1): buffer and are not chemically altered by UCH-L1.
Ki 
IC50
1 
[Ub  AMC]
KM
, (1) O-Acyl Oxime Compounds Promote Proliferation
of H1299 and SH-SY5Y Cells
To test the effect of UCH-L1 inhibitors in a cell culture
model, H1299 (an UCH-L1-expressing non-small cellwhere [Ub-AMC]  50 nM and the KM for the UCH-L1/
Ub-AMC reaction was 59 nM (Figure 4C). The average lung cancer [NSCLC]) and H358 (a NSCLC line that does
not express UCH-L1) (Figure 5A) [19] were treated withkcat,app was 0.049  0.006 s1 (Figure 4B) and is in agree-
ment with previous published data [9]. 5 M of 15, 30, 50, or 52. As negative controls, the cells
were also treated with 5 M of 24 (a relatively inactiveTo determine if the isatin O-acyl oximes are binding
at UCH-L1’s active site, different concentrations of 30 derivative: IC50  80 M) and pure DMSO. Cell growth
was quantified by counting the number of living cells as awere added to the UCH-L1/Ub-AMC reaction in the pres-
ence of a thiol alkylating agent. For example, in the function of time. The concentration of 5 M was chosen
because it is 2-fold or higher than the IC50s of com-presence of 20 mM iodoacetamide, UCH-L1 loses enzy-
matic activity, presumably by derivitization and inactiva- pounds 30, 50, and 52 toward UCH-L1, yet it is signifi-
cantly lower than all the compounds’ IC50s toward UCH-tion of the active site cysteine (Figure 4D). When increas-
ing amounts of 30 were added to the reaction mixture, L3. The cell counts of both the H358 (Figure 5C) and
H1299 (Figure 5B) lines increased by comparablethe rate of UCH-L1 inactivation by the alkylating reagent
was decreased (Figure 4E). This result indicated that amounts when treated with DMSO or 24. Two of the
potent compounds, 50 and 52, dramatically increasedbinding of the isatin O-acyl oxime protected the UCH-
L1 active site cysteine, supporting the hypothesis that proliferation of H1299 cells (none affected proliferation
Chemistry & Biology
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Figure 4. Compound 30 Is a Reversible Competitive Inhibitor
(A) Dependence of Vo/[E] on [Ub-AMC] at five fixed concentration of 30 (black, 0; red, 1 M; blue, 5 M; pink, 10 M; green, 25 M).
(B) Summary of KM,app and kcat,app values.
(C) Dependence of of KM,app on [30] yields KM of 59 nM and Ki of 0.40 M.
(D) Ub-AMC reaction progress curves in the presence or absence of iodoacetamide (20 mM).
(E) Normalized progress curves showing the amount of active UCH-L1 remaining in the reaction mixture in the presence of 20 mM iodoacetamide
and various concentrations of 30 (black, 0; red, 500 nM; yellow, 1 M; green, 3 M; blue, 5 M).
of H358 cells). The failure of the equipotent UCH-L1 details are critical in order to determine whether UCH-
inhibitor 30 to demonstrate significant proproliferative L1 represents a viable drug target for either of these
activity may be due to its inefficient transport into H1299 indications. As an alternative to treatment with small
cells; in fact, both 30 and 52 increased proliferation molecules, which most often are inhibitors, mouse mod-
of a UCH-L1-expressing neuroblastoma line (SH-SY5Y) els can be genetically manipulated to test the effect of
(see Supplemental Data at http://www.chembiol.com/ protein expression level (decrease and increase) on a
cgi/content/full/10/9/837/DC1). To test whether the ob- chosen phenotype. While a transgenic mouse that over-
served pro-proliferative activity was the result of inhibi- expresses UCH-L1 has not been reported, a mouse har-
tion of UCH-L1, the H1299 line was stably transfected boring a spontaneous deletion of a major portion of
with a UCH-L1 RNAi vector to suppress UCH-L1 expres- the UCH-L1 gene has been identified. Mice that are
sion. The H1299 line was also stably transfected with a homozygous for the deletion (a model of the completely
UCH-L1 expression vector to increase expression. In inhibited state) develop a neurodegenerative phenotype
the three H1299 lines, the expression level of UCH-L1 that is distinct from PD (gracile axonal dystrophy, gad)
inversely correlated with cell proliferation, in this case [8, 35–39]. Mice that are heterozygous for the deletion
measured by the MTT assay (Figure 5D). This result is express a significantly reduced amount of UCH-L1
consistent with the notion that the effect of the small (50%–80% of normal, a model of the partially inhibited
molecule inhibitors is mediated by UCH-L1 and that
state), yet are neurologically indistinguishable from the
UCH-L1 activity opposes proliferation. The change in
wild-type mice [8, 35–39]. Mice generated by crossingUCH-L1 expression level also resulted in a morphologi-
homozygous gad mice with UCH-L3 knockout mice ex-cal change in the H1299 cells (Figures 5E–5G). An in-
hibit a more severe neurodegenerative phenotype thancreasing level of UCH-L1 correlated with an increase in
the gad homozygotes (the UCH-L3 knockouts did notcell size and a morphology with more extended pro-
show any neurodegeneration) [8]. None of these micecesses, two phenomena that also have been observed
have been used in studies of tumorogenesis or neuro-in an acute lymphoblastic leukemia cell line, Reh [33,
pathic pain, which have also been linked to UCH-L1 [40].34]. Thus, in H1299 cells, UCH-L1 may affect the cell
The chemical genetic approach to UCH-L1 inhibitioncycle and cell growth without affecting the cell viability.
described here identified a class of isatin O-acyl oxime
derivatives that are reversible, active site-directed inhib-Discussion
itors and demonstrate good selectivity for UCH-L1 ver-
sus UCH-L3. We demonstrate that these inhibitors pro-The neuronal enzyme UCH-L1 is implicated in PD and
cancer, but the details of its role are unknown. These mote the growth of a lung tumor cell line, a result that
HTS for the Discovery of UCH-L1 Inhibitors
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Figure 5. UCH-L1 Inhibition in Lung Cancer Cell Lines
(A) UCH-L1 (Western blot at top) is expressed in the H1299 cell line (two right lanes), but not the H358 line (two left lanes). The Coomassie-
stained SDS-PAGE gel at bottom showed equal amounts of cell lysates were loaded.
(B and C) The H1299 (B) and H358 (C) cell lines showed a different sensitivity to small molecules (black, DMSO; red, 15; orange, 24; yellow,
30; green, 50; and blue, 52).
(D) UCH-L1 expression and cell proliferation (MTT assay) are inversely correlated in H1299 UCH-L1, H1299, and H1299 UCH-L1 RNAi cell
lines.
(E–G) A more differentiated cell morphology and larger cell size are associated with increasing expression of UCH-L1 in H1299 cells.
is consistent with UCH-L1’s antiproliferative effect ob- UCH-L1 expression drives tumor formation or is a re-
sponse to tumor proliferation. To enable a chemicalserved upon modulation of UCH-L1 expression level.
However, many questions remain to be answered. While genetic approach to this question, we undertook a
high-throughput screen of 42,000 drug-like com-promotion of UCH-L1 expression could slow tumor cell
proliferation, the downstream effect of UCH-L1 activity pounds to identify UCH-L1 inhibitors. Hits from this
screen were then modified to increase their potencyon cell migration and invasion, for example, may be
detrimental, as suggested by the positive correlation toward UCH-L1 and their selectivity against UCH-L3.
We report here the first class of small molecule UCH-of UCH-L1 expression with tumor stage, T-status, and
lower survival rate of the lung, colorectal, and pancreatic L1 inhibitors. Treatment of lung tumor lines with these
compounds indicated that UCH-L1 activity is antipro-cancer patients [17, 19, 22, 41]. Furthermore, we have
previously shown that UCH-L1 has two enzymatic activi- liferative and that its expression is probably induced
as a response to tumor growth. These compoundsties, a weak hydrolase activity and a unique ligase activ-
ity [9]. It remains an open question as to which enzymatic will facilitate investigation of the role of UCH-L1 in
Parkinson’s disease, cancer, and neuropathic pain.activity (or combination thereof) is responsible for the
reported antiproliferative effect in cancer cells. Using
the similar approach, we hope to find small molecules Experimental Procedures
that inhibit UCH-L1 ligase activity by disrupting UCH-
Chemicals and MaterialsL1 dimerization. These compounds will help to elucidate
All chemicals used in protein purification and enzymatic reactionsUCH-L1’s roles in the diverse pathways that contribute
were purchased from Sigma-Aldrich and used without purification.
to the pathogenesis of cancer and PD. Protein purification columns were purchased from Amersham Phar-
macia.
Significance
ProteinsUbiquitylation/deubiquitylation pathways are increas-
Plasmids for prokaryotic expression of UCH-L1 and UCH-L3 wereingly recognized as important in diverse cellular pro-
a gift from K. Wilkinson. Each plasmid was transformed intocesses in addition to proteasome-dependent protein
BL21(DE3) competent cells (Novagen). The transformed cells were
degradation. The abundant neuronal enzyme ubiquitin grown on LB plate containing ampicillin overnight at 37	C. LB cul-
C-hydrolase-L1 (UCH-L1) is involved in the growth of tures (7 ml) containing 0.15 mg/l ampicillin were each inoculated
with a single colony of transformed BL21(DE3) cell and shaken atsome nonneuronal tumors, but it is not clear whether
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250 rpm and 37	C. The overnight cultures were used to inoculate 2 Dose-Dependent Assays
Compounds that showed consistent activity toward UCH-L1 enzy-l of LB/ampicillin media for each enzyme expression. The cells were
shaken at 250 rpm and at 37	C until OD of 0.5 at 600 nm was matic activity through the primary and secondary screen were then
tested in a dose-dependent assay, also using 384-well plates. UCH-reached. IPTG (0.5 mM) was added to the cell culture to induce
protein expression. After 2–3 hr of additional incubation/shaking at L1/Ub-AMC reaction was performed with a series dilution of each
compound (100 M, 50 M, 20 M, 4 M, 800 nM, 160 nM, 32 nM,37	C, cells were harvested by centrifugation at 8000 rpm for 10 min
at 4	C. Cell pellets were resuspended in 100 ml of UCH protein 6.4 nM, 1.3 nM, and 260 pM). Compounds that did not exhibit dose-
dependent activity toward UCH-L1 were eliminated from the candi-buffer (50 mM Tris-HCl [pH 7.6], 0.5 mM EDTA, 1 mM DTT) in the
presence of PMSF and then lysed using a Microfluidizer Processor date list.
(9000). Streptomycin sulfate was added (final 1% weight/volume)
into each cell lysate and the mixtures were incubated on ice for 10 Quenching of AMC Fluorophore with Each
min prior to centrifugation at 10,000 rpm for 20 min at 4	C. The Inhibitor Compound
supernatant (30 ml for each run) was fractionated on HiTrap Q XL To eliminate a false positive due to fluorescence quenching of AMC
column (5 ml column volume) in UCH protein buffer with 0 to 600 amine by the test compound, a series of control experiments were
mM NaCl gradient using AKTA FPLC (Amersham Pharmacia). UCH performed in which 100 M of each compound was incubated in a
enzyme fractions were combined and dialyzed in UCH protein buffer solution containing 100 nM AMC amine. Compounds that quenched
overnight at 4	C. For UCH-L1 protein purification, the collected pro- AMC amine fluorescence were removed from the initial library.
tein samples were furthered purified using a HiTrap Benzamidine
column (1 ml column volume) in UCH protein buffer with 0 to 600 IC50 Value Determinations
mM NaCl grandient. Instead of using a benzamidine column, UCH- Various concentrations (100 M to 50 nM) of compound dissolved
L3 was subjected to gel filtration column purification using a HiLoad in DMSO were each added to 2 ml of 1 nM UCH-L1 or 50 pM UCH-
16/60 Superdex 75 preparative grade gel filtration column equili- L3 in UCH reaction buffer and incubated at 25	C for 30 min. Ubiquitin
brated with UCH buffer. Fractions containing UCH enzymes were C-terminal hydrolysis activity was initiated by adding 2 l of 50 M
combined and dialyzed in UCH protein buffer overnight at 4	C. The ubiquitin-AMC. The reactions were monitored at 25	C using a Hitachi
proteins were aliquoted into small volume and stored at 80	C. F4500 fluorescence spectrophotometer. The AMC fluorophore was
SDS-PAGE showed that the proteins were 98% pure and protein excited at 380 nm and the rates of release of free AMC were mea-
concentrations were determined by amino acid analysis. sured by monitoring the increase in fluorescence emission at 460
nm. The initial velocity Vo was measured for each reaction and
plotted against compound concentrations in order to determine theHTS for UCH-L1 Inhibitors
IC50 values using GraFit V.5 software (Erithacus Software, UK).The compound library used for screening against UCH-L1 contained
42,000 molecules purchased from Prestwick (Illkirch, France),
Ki Value Determination for Compound 30Specs and Biospecs (CP Rijswijk, Netherlands), Bionet Research
Various concentrations of compound 30 (0, 1 M, 5 M, 10 M, andLtd. (Cornwall, UK), Maybridge Plc. (Cornwall, UK), Cerep (Paris,
25 M) dissolved in DMSO were each added to 2 ml of 1 nM UCH-France), Peakdale (High Peak, UK), and Chemical Diversity Labs,
L1 in UCH reaction buffer and incubated at 25	C for 30 min. UbiquitinInc. (San Diego, CA). The compound libraries were delivered predis-
C-terminal hydrolysis activity was initiated by adding varioussolved in DMSO or in powdered form in 96-well tube racks. The
amounts of 100 M ubiquitin-AMC stock solution to give a rangepowdered compounds were reconstituted in DMSO to 5 mg/ml.
of final concentrations between 10 nM and 2 M. The reactionsFour 96-well tube racks were combined into each 384-well master
were monitored at 25	C using a Hitachi F4500 fluorescence spectro-plate, via the quadrant mapping system. All compounds were stored
photometer. The initial velocity Vo was measured for each reactionat 20	C prior to use.
and plotted against Ub-AMC concentrations in order to determineThe HTS screen was performed on a Beckman Coulter Biomek
the KM,app and kcat,app. The KM and Ki values were determined from theFX liquid handling station integrated into a Saigian core system built
linear fit of KM,app versus [30].around an ORCA robotic arm. This core system consists of a plate
washer, plate shaker, temperature- and CO2-controlled incubator,
Compound 30 Titration in UCH-L1/Iodoacetamide Reactionsand plate carousel for storage. To start an assay, 0.5 l of 5 mg/ml
UCH-L1 enzymatic activity in the presence or absence of iodoacet-test compound (about 50 M final reaction concentration) or DMSO
amide was monitored using Ub-AMC substrate in UCH reactioncontrol was aliquoted into each well. Both enzyme and substrate
buffer. Iodoacetamide (20 mM) was added to the 5 nM UCH-L1 andwere prepared in UCH reaction buffer (50 mM Tris-HCl [pH 7.6], 0.5
200 nM UbAMC reaction mixtures within 1 min after the reactionsmM EDTA, 5 mM DTT, and 0.5 mg/ml ovalbumin). 25 l of 0.6 nM
were started. To characterize the effect of 30 on UCH-L1 inactivationUCH-L1 was then added to each well except substrate control wells,
by iodoacetamide, various amounts (500 nM to 5 M) of 30 werefollowed by plate shaking for 45–60 s on an automatic shaker. The
incubated with UCH-L1 for 5 min prior to the initiation of the Ub-enzyme/compound mixture was incubated at room temperature for
AMC reaction followed by addition of iodoacetamide. The progress30 min before 25 l of 200 nM Ub-AMC (Boston Biochem, Cam-
curves for the reactions containing iodoacetamide and/or 30 werebridge, MA) was added to initiate the enzyme reaction. The reaction
normalized by the final AMC product fluorescence emission intensitymixture (300 pM UCH-L1, 100 nM Ubiquitin-AMC with 2.5 g test
[(Finfinite  Ft)/(Finfinite  Ft0) 
 100].compound) was incubated at room temperature for 30 additional
minutes prior to quenching the reaction by the addition of 10 l 500
mM acetic acid per well. The fluorescence emission intensity was General Procedure for the Preparation of O-Acyloxime
Isatins, Exemplified for 30 (LDN-57444)measured on a LJL Analyst using a coumarin filter set (ex  365
nm, em  450 nm) and was subtracted by the intrinsic compound To a solution of 5-chloroisatin (182 mg, 1.0 mmol) in anhydrous
dimethylformamide (4 ml) was added sodium hydride (60 mg, 60%fluorescence to reveal the enzyme activity. A DMSO control (0.5 l
of DMSO, 25 l of UCH-L1, 25 l of ubiquitin-AMC, 10 l of acetic dispersion in mineral oil, 5 mmol) at 0	C under an argon atmosphere.
The mixture was stirred at room temperature for 30 min before theacid), enzyme control (25 l of UCH-L1, 25 l of buffer, 10 l of
acetic acid), substrate control (25 l of buffer, 25 l of ubiquitin- addition of 2, 5-dichlorobenzyl chloride (240 mg, 1.0 mmol). The
resulting mixture was stirred overnight. The reaction mixture wasAMC, 10 l of acetic acid), and inhibitor control (0.5 l of ubiquitin
aldehyde [100 nM stock], 25 l of UCH-L1, 25 l of ubiquitin-AMC, diluted with EtOAc (60 ml), washed with brine (10 ml), dried over
anhydrous MgSO4, filtered, and concentrated. The residue was puri-10 l of acetic acid) were also performed in each assay plate to
ensure quality and reproducibility. Potential UCH-L1 inhibitors were fied by column chromatography on silica gel using hexane/ethyl
acetate (2:1) as eluent to give N-(2, 5-dichlorobenzyl)-5-chloroisatinselected if the compounds demonstrated greater than 60% inhibi-
tion compared to the controls. The UCH-L1 enzymatic reactions (204 mg, 60% yield) as a red solid. 1H NMR (500 MHz, CDCl3):  5.02
(s, 2H), 6.72 (d, 1H, J  8.5 Hz), 7.18 (d, 1H, J  2.5 Hz), 7.26 (dd,were manually repeated twice using the same protocol to confirm
the results for the hit compounds from the primary robot-assisted 1H, J  2.5, 8.5 Hz), 7.38 (d, 1H, J  8.5 Hz), 7.50 (dd, 1H, J  2.5,
8.5 Hz), 7.64 (d, 1H, J  2.5 Hz).screen.
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To a solution of N-(2, 5-dichlorobenzyl)-5-chloroisatin (34 mg, 0.1 References
mmol) in MeOH/THF (1:1, 2 ml) were added hydroxylamine hydro-
chloride (140 mg, 2.0 mmol) and sodium acetate (166 mg, 2.0 mmol). 1. Wilkinson, K.D., Lee, K.M., Deshpande, S., Duerksen-Hughes,
P., Boss, J.M., and Pohl, J. (1989). The neuron-specific proteinThe mixture was stirred at room temperature overnight, then diluted
with EtOAc (40 ml), washed with saturated NaHCO3 (10 ml) and brine PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 246,
670–673.(10 ml), dried over anhydrous MgSO4, filtered, and concentrated.
The crude N-(2, 5-dichlorobenzyl)-5-chloroisatin oxime was used 2. Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey,
E., Harta, G., Brownstein, M.J., Jonnalagada, S., Chernova, T.,without further purification.
To a solution of the oxime (0.1 mmol) in dry pyridine (2 ml) was et al. (1998). The ubiquitin pathway in Parkinson’s disease. Na-
ture 395, 451–452.added acetic anhydride (0.5 ml, mmol) at room temperature under
an argon atmosphere. The mixture was stirred for 2 hr and then 3. Larsen, C.N., Price, J.S., and Wilkinson, K.D. (1996). Substrate
binding and catalysis by ubiquitin C-terminal hydrolases: identi-partitioned between ethyl acetate (30 ml) and 1 N HCl (10 ml). The
organic layer was washed sequentially with 1N HCl (10 ml), saturated fication of two active site residues. Biochemistry 35, 6735–6744.
4. Larsen, C.N., Krantz, B.A., and Wilkinson, K.D. (1998). SubstrateNaHCO3 (5 ml), and brine (10 ml), dried over anhydrous MgSO4,
specificity of deubiquitinating enzymes: ubiquitin C-terminal hy-filtered, and concentrated. The product was purified by column
drolases. Biochemistry 37, 3358–3368.chromatography on silica gel using hexane/ethyl acetate (2:1) to
5. Wilkinson, K.D. (1997). Regulation of ubiquitin-dependent pro-give 30 as a pale yellow solid (35 mg, 87% yield over two steps).
cesses by deubiquitinating enzymes. FASEB J. 11, 1245–1256.mp 178	C–181	C; 1H NMR (500 MHz, CDCl3):  2.50 (s, 3H), 5.03 (s,
6. Dang, L.C., Melandri, F.D., and Stein, R.L. (1998). Kinetic and2H), 6.68 (d, 1H, J  8.5 Hz), 7.12 (d, 1H, J  2.5 Hz), 7.23 (dd, 1H,
mechanistic studies on the hydrolysis of ubiquitin C-terminalJ  2.5, 8.5 Hz), 7.36 (d, 1H, J  8.5 Hz), 7.39 (dd, 1H, J  2.0, 9.0
7-amido-4-methylcoumarin by deubiquitinating enzymes. Bio-Hz), 8.05 (d, 1H, J  2.0 Hz); 13C NMR (100.5 MHz, CDCl3):  19.72
chemistry 37, 1868–1879.(CH3), 41.43 (CH2), 111.10 (CH), 116.12 (C), 128.23 (CH), 129.55 (C),
7. Chung, C.H., and Baek, S.H. (1999). Deubiquitinating enzymes:129.68 (CH), 129.78 (CH), 131.26 (CH), 131.33 (C), 133.81 (2
C),
their diversity and emerging roles. Biochem. Biophys. Res.134.64 (CH), 142.98 (C), 147.06 (C), 162.57 (C), 168.32 (C); FT-IR
Commun. 266, 633–640.(KBr, max, cm1): 3444w, 3070w, 2924m, 2852w, 1785s, 1731s, 1608s,
8. Kurihara, L.J., Kikuchi, T., Wada, K., and Tilghman, S.M. (2001).1471s, 1442m, 1338m, 1170s, 928s, 917s, 826m; Elemental Analysis
Loss of Uch-L1 and Uch-L3 leads to neurodegeneration, poste-calculated for C17H11Cl3N2O3: C, 51.35; H, 2.79; N, 7.04; found: C,
rior paralysis and dysphagia. Hum. Mol. Genet. 10, 1963–1970.51.31; H, 3.19; N, 6.84.
9. Liu, Y., Fallon, L., Lashuel, H.A., Liu, Z., and Lansbury, P.T., Jr.
(2002). The UCH-L1 gene encodes two opposing enzymatic
Cell-Base O-Acyl Oxime Compound Assays activities that affect alpha-synuclein degradation and Parkin-
H1299 and H358 non-small cell lung cancer cell lines were pur- son’s disease susceptibility. Cell 111, 209–218.
chased from American Type Culture Collection (ATCC) and were 10. Maraganore, D.M., Farrer, M.J., Hardy, J.A., Lincoln, S.J.,
maintained in RPMI medium (ATCC) containing 10% fetal bovine McDonnell, S.K., and Rocca, W.A. (1999). Case-control study of
serum. Cells were cultured at 37	C for 24 hr prior to treatments with the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson’s
the 5 M 15, 24, 30, 50, 52, or DMSO. Cells were counted under disease. Neurology 53, 1858–1860.
light microscope at each time point. 11. Levecque, C., Destee, A., Mouroux, V., Becquet, E., Defebvre,
L., Amouyel, P., and Chartier-Harlin, M.C. (2001). No genetic
association of the ubiquitin carboxy-terminal hydrolase-L1 gene
Transfection of H1299 Cells with UCH-L1 Expressing and S18Y polymorphism with familial Parkinson’s disease. J. Neural
RNAi Vectors Transm. 108, 979–984.
UCH-L1 was cloned into pcDNA3.1 (Invitrogen) with restriction en- 12. Satoh, J.I., and Kuroda, Y. (2001). Ubiquitin C-terminal hy-
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